Syndax
Stock
Stock
Ticker: SNDX
SNDX
Price
Price
CHART BY
Frequently asked questions
What is Syndax's market capitalization?
The market capitalization of Syndax is $1.17B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Syndax?
Syndax's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$2.518. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Syndax's stock?
Currently, 12 analysts cover Syndax's stock, with a consensus target price of $37.27. Analyst ratings provide insights into the stock's expected performance.
What is Syndax's revenue over the trailing twelve months?
Over the trailing twelve months, Syndax reported a revenue of $252.25M.
What is the EBITDA for Syndax?
Syndax's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$194.16M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Syndax?
Syndax has a free cash flow of -$220.87M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Syndax have, and what sector and industry does it belong to?
Syndax employs approximately 298 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Syndax's shares?
The free float of Syndax is 81.16M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $1.17B
- EPS (TTM)
- -$2.518
- Free Float
- 81.16M
- Revenue (TTM)
- $252.25M
- EBITDA (TTM)
- -$194.16M
- Free Cashflow (TTM)
- -$220.87M
Pricing
- 1D span
- $13.55$13.57
- 52W span
- $12.80$25.55
Analyst Ratings
The price target is $37.27 and the stock is covered by 12 analysts.
Buy
12
Hold
0
Sell
0
Information
Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include Revuforj and Niktimvo. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.
- Employees
- 298
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- SNDX
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet